论文信息 - Etravirine‐based highly active antiretroviral therapy in HIV‐1‐infected paediatric patients - 字舞流文

Etravirine‐based highly active antiretroviral therapy in HIV‐1‐infected paediatric patients

We evaluated the efficacy, safety and tolerability of etravirine in paediatric patients vertically infected with HIV‐1.

M. Navarro | M. Muñoz-Fernandez | V. Briz | S. Jiménez de Ory | C. Palladino | M. González-Tomé | E. Núñez-Cuadros | J. Ramos | J. León | MI de José

[1] V. Calvez,et al. Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naïve Patients Infected with Non-B HIV-1 Subtypes , 2009, Antimicrobial Agents and Chemotherapy.

[2] C. Rouzioux,et al. Risk of Extended Viral Resistance in Human Immunodeficiency Virus-1-Infected Mozambican Children After First-Line Treatment Failure , 2009, The Pediatric infectious disease journal.

[3] P. Frange,et al. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus , 2009, AIDS.

[4] R. Haubrich,et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials , 2009, AIDS.

[5] Raquel Lorente,et al. The Spanish HIV BioBank: a model of cooperative HIV research , 2009, Retrovirology.